Exenatide

Exenatide is a 39-amino-acid peptide amide — the synthetic form of exendin-4, a peptide isolated from the venom of the Gila monster by John Eng in 1992. It shares ~53% homology with human GLP-1 but is naturally resistant to DPP-4 degradation, giving it therapeutic durability. It holds a landmark place in pharmacology as the first GLP-1 receptor agonist approved by the FDA (April 28, 2005), launching the entire incretin-mimetic class. It was sold as Byetta® (twice-daily) and later in once-weekly extended-release form as Bydureon® (2012) and Bydureon BCise® (2017). As of August 2026, Drugs@FDA lists all three brand products as discontinued; exenatide remains on the US market as a generic twice-daily injection, approved in November 2024 referencing Byetta. Research-market material is RUO.

Sources: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas, Eng J. et al. (optional, non-blocking: complete list — Kleinman W.A., Singh L., Singh G., Raufman J.P. per standard citation, not rendered this session), J Biol Chem, 1992; BYETTA (NDA 021773) · BYDUREON/BYDUREON PEN (NDA 022200) · BYDUREON BCISE (NDA 209210) — Drugs@FDA approval + marketing status, FDA (applicant AstraZeneca AB), via Drugs@FDA; Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist, Amneal Pharmaceuticals, via investors.amneal.com (company press release)

What is Exenatide and why does its exendin-4 origin matter?

Exenatide is a naturally DPP-4-resistant GLP-1 receptor agonist because its exendin-4 sequence differs enough from human GLP-1 to evade the enzyme that degrades native GLP-1 within minutes — the insight that made durable incretin therapy possible. It set the template that later agents (semaglutide, liraglutide) refined.

Evidence level: FDA-approved (human clinical pharmacology)

What does the clinical evidence show?

Exenatide has a mature approved evidence base for glycemic control in type 2 diabetes, with modest associated weight loss (typically 2–4 kg); it is not approved for weight management or (unlike newer agents) cardiovascular risk reduction with the same strength.

Evidence level: FDA-approved (human RCTs)

How does exenatide compare with semaglutide, tirzepatide, and retatrutide?

Exenatide is the historical first — the molecule that proved the GLP-1 class in 2005 — but it is the least potent member for weight. It is the exendin-4 sequence (Gila-monster-venom origin, naturally DPP-4-resistant, ~2.4-hour half-life, twice-daily), where the newer agents are long-acting engineered analogs of human GLP-1 dosed weekly. Exenatide was never approved for weight management. Figures below are each trial's own published result, not head-to-head.

Source: EXENATIDE injection (generic, referencing BYETTA) — US Prescribing Information, Amneal Pharmaceuticals LLC (labeler), via DailyMed · Evidence level: FDA-approved (human RCTs); retatrutide Phase 2

Browse the full weight-loss & metabolic peptide category.

What are the documented side effects of Exenatide?

The most common effects are gastrointestinal (nausea especially); documented risks include pancreatitis and a thyroid C-cell tumor warning for the extended-release form (contraindicated in medullary thyroid carcinoma history or MEN2).

Evidence level: FDA labeling

What is the regulatory status, and how does research-market material differ?

Exenatide is FDA-approved — historically as Byetta/Bydureon, whose brand products are now listed as discontinued in Drugs@FDA, and currently as a generic twice-daily injection (approved November 2024, referencing Byetta) — but research-market material is not the approved product and its identity cannot be assumed — see the legal status guide.

Sources: BYETTA (NDA 021773) · BYDUREON/BYDUREON PEN (NDA 022200) · BYDUREON BCISE (NDA 209210) — Drugs@FDA approval + marketing status, FDA (applicant AstraZeneca AB), via Drugs@FDA; Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist, Amneal Pharmaceuticals, via investors.amneal.com (company press release)

Why does vendor verification matter, and how does Peptigrity verify?

HPLC purity and mass-spec identity (expected MW ~4187 Da) are the objective checks for a research-market 39-mer peptide, where truncation and mislabeling are real risks. Peptigrity collects independent third-party Certificates of Analysis for exenatide from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The trust score weights lab purity and reviews equally (50/50). Compare any vendor claim against the independent exenatide lab tests on file. See how to read lab results.

Source: EXENATIDE injection (generic, referencing BYETTA) — US Prescribing Information, Amneal Pharmaceuticals LLC (labeler), via DailyMed

This section is for educational and informational purposes only and does not constitute medical advice. Research-grade exenatide sold for laboratory use is not an FDA-approved product. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.

Frequently asked questions